Exhibit 99.1 Veracyte Announces Second Quarter 2024 Financial Results Grew total revenue to $114.4 million, an increase of 27% Grew testing revenue by 31% Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., August 6, 2024 --- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the second quarter ended June 30, 2024. "Our exceptional second quarter results are a testament to the strength and robustness of Decipher and Afirma," said Marc Stapley, Veracyte's chief exe ...

This molecular diagnostic company is expected to post quarterly loss of $0.03 per share in its upcoming report, which represents a year-over-year change of +75%. Revenues are expected to be $100.34 million, up 11.1% from the year-ago quarter. For Veracyte, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on VCYT going forward ...

But what's the best way to find the right combination of stocks? Because funding things like your retirement, your kids' college tuition, or your short- and long-term savings goals will definitely require significant returns. What is the Zacks Rank? Agreement is the extent to which all brokerage analysts are revising their earnings estimates in the same direction. The greater the percentage of analysts revising their estimates higher, the better chance the stock will outperform. Upside is the difference bet ...

Inventory Turnover, Receivables Turnover, Asset Utilization, and Operating Margin greater than the industry average Veracyte (VCYT) is a global diagnostics company that provides clinicians with valuable insights to diagnose and treat cancer. VCYT has an average four-quarter earnings surprise of 59.7%. The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, ...

A month has gone by since the last earnings report for Veracyte (VCYT) . Shares have added about 8.4% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Veracyte due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Veracyte's Q1 Loss Lower Than Expected,'24 Sales View Up ...

Veracyte (VCYT) closed the last trading session at $21.45, gaining 9.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $29.83 indicates a 39.1% upside potential. The mean estimate comprises six short-term price targets with a standard deviation of $5.71. While the lowest estimate of $21 indicates a 2.1% decline from the current price level, the most optimistic analyst expects the ...

Over the past four weeks, VCYT has gained 9.6%. The company is currently ranked a Zacks Rank #1 (Strong Buy), another strong indication the stock could move even higher. Once investors consider VCYT's positive earnings estimate revisions, the bullish case only solidifies. No estimate has gone lower in the past two months for the current fiscal year, compared to 2 higher, and the consensus estimate has increased as well. Given this move in earnings estimate revisions and the positive technical factor, invest ...

Irrespective of market conditions, companies with favorable efficiency levels are more likely to be investors' choices. The reason is that a company with a favorable efficiency level is expected to offer impressive returns as it is believed to be positively correlated to its price performance. Efficiency ratio is an indication of a company's financial health. It analyzes how efficiently a company uses its assets and liabilities internally. However, at times it becomes difficult to measure the efficiency lev ...

Veracyte, Inc. (VCYT) , a leading name in cancer diagnostics, is set to showcase compelling data from three studies demonstrating the capabilities of its Afirma GRID (Genomic Resource for Intelligent Discovery) tool at ENDO 2024 from Jun 1-4. These findings promise to enhance the personalization of thyroid cancer treatment, marking a significant step forward in the molecular testing landscape. By enhancing the depth and accuracy of molecular testing, Veracyte's Afirma GRID tool is poised to play a crucial r ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36156 VERACYTE, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I ...